Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Journal of Chemical Information and Modeling
|
April 26, 2021
Toward an Understanding of Pan-Assay Interference Compounds and Promiscuity: A Structural Perspective on Binding Modes
Sarah Naomi Bolz, Melissa F Adasme, Michael Schroeder
Seminars in Cancer Biology
|
February 8, 2020
Structure-based drug repositioning: Potential and limits
Melissa F Adasme, Daniele Parisi, Anastasia Sveshnikova, et al.
Journal of Cheminformatics
|
March 16, 2022
Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening
Melissa F Adasme, Sarah Naomi Bolz, Ali Al-Fatlawi, et al.
Nucleic Acids Research
|
April 16, 2015
PLIP: fully automated protein-ligand interaction profiler
Sebastian Salentin, Sven Schreiber, V Joachim Haupt, et al.
Computational and Structural Biotechnology Journal
|
May 19, 2020
Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs
Daniele Parisi, Melissa F Adasme, Anastasia Sveshnikova, et al.
Scientific Reports
|
September 14, 2017
From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns
Sebastian Salentin, Melissa F Adasme, Jörg C Heinrich, et al.
Nucleic Acids Research
|
May 5, 2021
PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA
Melissa F Adasme, Katja L Linnemann, Sarah Naomi Bolz, et al.
Journal of Cheminformatics
|
February 12, 2026
Integrating artificial intelligence and manual curation to enhance bioassay annotations in ChEMBL
Ines Smit, Melissa F Adasme, Emma Manners, et al.
Journal of Cheminformatics
|
March 28, 2026
Correction: Integrating artificial intelligence and manual curation to enhance bioassay annotations in ChEMBL
Ines Smit, Melissa F Adasme, Emma Manners, et al.
Plos One
|
May 28, 2020
Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor
Melissa F Adasme, Daniele Parisi, Kristien Van Belle, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Journal of Chemical Information and Modeling
|
April 26, 2021
Toward an Understanding of Pan-Assay Interference Compounds and Promiscuity: A Structural Perspective on Binding Modes
Sarah Naomi Bolz, Melissa F Adasme, Michael Schroeder
Seminars in Cancer Biology
|
February 8, 2020
Structure-based drug repositioning: Potential and limits
Melissa F Adasme, Daniele Parisi, Anastasia Sveshnikova, et al.
Journal of Cheminformatics
|
March 16, 2022
Decomposing compounds enables reconstruction of interaction fingerprints for structure-based drug screening
Melissa F Adasme, Sarah Naomi Bolz, Ali Al-Fatlawi, et al.
Nucleic Acids Research
|
April 16, 2015
PLIP: fully automated protein-ligand interaction profiler
Sebastian Salentin, Sven Schreiber, V Joachim Haupt, et al.
Computational and Structural Biotechnology Journal
|
May 19, 2020
Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs
Daniele Parisi, Melissa F Adasme, Anastasia Sveshnikova, et al.
Scientific Reports
|
September 14, 2017
From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns
Sebastian Salentin, Melissa F Adasme, Jörg C Heinrich, et al.
Nucleic Acids Research
|
May 5, 2021
PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA
Melissa F Adasme, Katja L Linnemann, Sarah Naomi Bolz, et al.
Journal of Cheminformatics
|
February 12, 2026
Integrating artificial intelligence and manual curation to enhance bioassay annotations in ChEMBL
Ines Smit, Melissa F Adasme, Emma Manners, et al.
Journal of Cheminformatics
|
March 28, 2026
Correction: Integrating artificial intelligence and manual curation to enhance bioassay annotations in ChEMBL
Ines Smit, Melissa F Adasme, Emma Manners, et al.
Plos One
|
May 28, 2020
Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor
Melissa F Adasme, Daniele Parisi, Kristien Van Belle, et al.
Page
of 2